4.5 Article

The Impact of Obesity on the Rise in Esophageal Adenocarcinoma Incidence: Estimates from a Disease Simulation Model

期刊

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
卷 20, 期 11, 页码 2450-2456

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1055-9965.EPI-11-0547

关键词

-

资金

  1. AstraZeneca Pharmaceuticals
  2. Ironwood Pharmaceuticals Inc.
  3. Takeda Pharmaceutical Company Ltd.
  4. XenoPort, Inc.
  5. Torax Medical, Inc.
  6. BARRX Medical, Inc.
  7. GE Healthcare
  8. National Cancer Institute at the NIH [U01CA152926, R01CA140574, K25CA133141, R00CA126147]

向作者/读者索取更多资源

Background: The United States has experienced an alarming and unexplained increase in the incidence of esophageal adenocarcinoma (EAC) since the 1970s. A concurrent increase in obesity has led some to suggest a relationship between the two trends. We explore the extent of this relationship. Methods: Using a previously validated disease simulation model of white males in the United States, we estimated EAC incidence 1973 to 2005 given constant obesity prevalence and low population progression rates consistent with the early 1970s. Introducing only the observed, rising obesity prevalence, we calculated the incremental incidence caused by obesity. We compared these with EAC incidence data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registry to determine obesity's contribution to the rise therein. Incidences were converted to absolute numbers of cases using U. S. population data. Results: Using constant obesity prevalence, we projected a total of 30,555 EAC cases cumulatively over 1973 to 2005 and 1,151 in 2005 alone. Incorporating the observed obesity trend resulted in 35,767 cumulative EACs and 1,608 in 2005. Estimates derived from SEER data showed 111,223 cumulative and 7,173 cases in 2005. We conclude that the rise in obesity accounted for 6.5% of the increase in EAC cases that occurred from 1973 to 2005 and 7.6% in the year 2005. Conclusion: Using published OR for EAC among obese individuals, we found that only a small percentage of the rise in EAC incidence is attributable to secular trends in obesity. Impact: Other factors, alone and in combination, should be explored as causes of the EAC epidemic. Cancer Epidemiol Biomarkers Prev; 20(11); 2450-6. (C) 2011 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据